Don't miss Edison's Soo Romanoff's interview with our CEO Gunnar Olsson, covering the company's action plan and strategic priorities going forward.
IRLAB Therapeutics AB (IRLAB-A) is a Sweden-based #biotechnology company focused on developing novel drugs for the treatment of #neurodegenerative diseases, with a particular emphasis on Parkinson’s disease, utilising its Integrative Screening Process proprietary drug discovery platform. In this interview, Edison’s Soo Romanoff talks to IRLAB’s CEO Gunnar Olsson about the company’s action plan and strategic priorities as it approaches these inflection points. Watch full interview here: https://lnkd.in/g6RtkAXr #OMX #IRLAB-A #parkinsonsdisease #irlabtherapeutics #NDD #drugdevelopment #drugdiscovery